CURRENT RESPECTIVE PLACE OF SURGERY AND PERMANENT INTRACARDIAC PACING IN THE TREATMENT OF HYPERTROPHIC CARDIOMYOPATHY

被引:0
作者
MILLAIRE, A
DEGROOTE, P
DECOULX, E
DUCLOUX, G
机构
来源
ANNALES DE CARDIOLOGIE ET D ANGEIOLOGIE | 1995年 / 44卷 / 05期
关键词
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Surgery and cardiac pacing are the two main non-drug treatments for hypertrophic cardiomyopathy. Various surgical techniques have been propsed over the last 35 years : myotomy, myotomy-septal myomectomy, isolated mitral valve replacement, heart transplantation. Patients eligible for surgery are those with severe symptoms (NYHA stage III or IV) and refractory or no longer responding to drug treatment. The choice between the various techniques is based on morphological and haemodynamic criteria (significant subaortic gradient associated with increased septal thickness, severe and/or organic mitral regurgitation, either isolated or associated with obstruction, or less severe or heterogeneous septal thickness [<18 mm]) or therapeutic criteria (failure of primary myomectomy, depletion of all surgical possibilities). Analysis of the results of surgery is complicated by the variety of techniques performed and the experience of the various teams. The operative mortality was markedly decreased (between 2 and 11 % at the present time); the complications of myomectomy (ventricular septal defect, disturbances of conduction requiring continuous pacing) are still frequent. Intraoperative transoesophageal ultrasonography could help to further decrease the operative risk. Surgery improves functional symptoms and exercise tolerance. This beneficial effect appears to be more marked, more frequent and more lasting than that of medical treatment. Surgical treatment does not ensure permanent cure, as the symptoms related to pathophysiological abnormalities other than intraventricular obstruction (abnormalities of diastolic filling, myocardial ischaemia, arrhythmias) may develop subsequently. No controlled trial has demonstrated a favourable effect survival. Continuous pacing, introduced more recently, can now be considered to be a therapeutic method in its own right. The benefit provided by continuous pacing appears to be equivalent to that of surgery (on symptoms, exercise capacity, intraventricular gradient) with a negligible risk compared to that of surgery. This has led a number of authors to propose continuous pacing as second-line treatment after failure of medical treatment and before resorting to surgery.
引用
收藏
页码:226 / 233
页数:8
相关论文
共 50 条
  • [32] Medical treatment of patients with hypertrophic cardiomyopathy: An overview of current and emerging therapy
    Iavarone, Michele
    Monda, Emanuele
    Vritz, Olga
    Albert, Dimpna Calila
    Rubino, Marta
    Verrillo, Federica
    Caiazza, Martina
    Lioncino, Michele
    Amodio, Federica
    Guarnaccia, Natale
    Gragnano, Felice
    Lombardi, Raffaella
    Esposito, Giovanni
    Bossone, Eduardo
    Calabro, Paolo
    Losi, Maria Angela
    Limongelli, Giuseppe
    ARCHIVES OF CARDIOVASCULAR DISEASES, 2022, 115 (10) : 529 - 537
  • [33] Revisiting Diagnosis and Treatment of Hypertrophic Cardiomyopathy: Current Practice and Novel Perspectives
    Ottaviani, Andrea
    Mansour, Davide
    Molinari, Lorenzo V.
    Galanti, Kristian
    Mantini, Cesare
    Khanji, Mohammed Y.
    Chahal, Anwar A.
    Zimarino, Marco
    Renda, Giulia
    Sciarra, Luigi
    Pelliccia, Francesco
    Gallina, Sabina
    Ricci, Fabrizio
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (17)
  • [35] One year follow up after randomised pacing on/off treatment for hypertrophic obstructive cardiomyopathy (HOCM)
    Kappenberger, LL
    Linde, C
    Daubert, C
    McKenna, WJ
    Meisel, E
    Sadoul, N
    Chojnowska, L
    Guize, L
    Gras, D
    Jeanrenaud, X
    Ryden, L
    CIRCULATION, 1997, 96 (08) : 2585 - 2585
  • [36] Analysis of dual-chamber pacing as a treatment for refractory limiting symptoms in patients with obstructive hypertrophic cardiomyopathy
    Maron B.J.
    Current Cardiology Reports, 2000, 2 (2) : 131 - 133
  • [37] Transcoronary ablation of septal hypertrophy compared with surgery in the treatment of hypertrophic obstructive cardiomyopathy
    姜腾勇
    吴学思
    吕强
    孟旭
    贾长琪
    张银
    中华医学杂志(英文版), 2004, (02) : 138 - 140
  • [38] Transcoronary ablation of septal hypertrophy compared with surgery in the treatment of hypertrophic obstructive cardiomyopathy
    Jiang, TY
    Wu, XS
    Lu, Q
    Meng, X
    Jia, CQ
    Yin, Z
    CHINESE MEDICAL JOURNAL, 2004, 117 (02) : 296 - 298
  • [39] Transcoronary ablation of septal hypertrophy compared with surgery in the treatment of hypertrophic obstructive cardiomyopathy
    姜腾勇
    吴学思
    吕强
    孟旭
    贾长琪
    张银
    Chinese Medical Journal, 2004, (02)
  • [40] Impact of right atrial-left ventricular dual-chamber permanent pacing in patients with severely symptomatic hypertrophic obstructive cardiomyopathy
    Honda, T
    Shono, H
    Koyama, J
    Tsuchiya, T
    Hayashi, M
    Hirayama, T
    Uesugi, H
    Honda, T
    CIRCULATION JOURNAL, 2005, 69 (05) : 536 - 542